Anticancer drugs are prescribed and administrated to an increasing number of patients on a daily basis. As a consequence, a number of concerns have been raised about the patient health and safety in the case that the drugs administered are not at the required concentration or even worse not the correct ones. Quality control of therapeutic solutions has therefore been extensively implemented in hospital environments, in order to avoid any failure in the intense workflow faced by administering pharmacists. In the present study, infrared (IR) and Raman spectroscopy have been Factorial Discriminant Analysis (PCA-FDA) highlights that, depending on the data preprocessing applied to Raman spectra, the discrimination between the 3 drugs is decreased, with in some cases specificity and sensitivity below 50%. However, IR analysis displays encouraging results with an overall specificity and sensitivity between 99-100%, suggesting that reliable validation of the therapeutic solution for administration to patients can be achieved. IR and Raman spectroscopy could assist and support quality control of chemotherapeutic solutions prepared in personalised concentrations for each patient. The effective and reliable characterisation of therapeutic solutions could have a lot to offer to improve current practices in a near future.
Abstract:
Anticancer drugs are prescribed and administrated to an increasing number of patients on a daily basis. As a consequence, a number of concerns have been raised about the patient health and safety in the case that the drugs administered are not at the required concentration or even worse not the correct ones. Quality control of therapeutic solutions has therefore been extensively implemented in hospital environments, in order to avoid any failure in the intense workflow faced by administering pharmacists. In the present study, infrared (IR) and Raman spectroscopy have been Factorial Discriminant Analysis (PCA-FDA) highlights that, depending on the data preprocessing applied to Raman spectra, the discrimination between the 3 drugs is decreased, with in some cases specificity and sensitivity below 50%. However, IR analysis displays encouraging results with an overall specificity and sensitivity between 99-100%, suggesting that reliable validation of the therapeutic solution for administration to patients can be achieved. IR and Raman spectroscopy could assist and support quality control of chemotherapeutic solutions prepared in personalised concentrations for each patient. The effective and reliable characterisation of therapeutic solutions could have a lot to offer to improve current practices in a near future.
I. Introduction:
Evolutions of clinical procedures and protocols in recent years are motivated by improvement of patient safety. Anticancer drugs are extensively used on a daily basis, the number of patients treated still increasing annually. Errors in medications are the main risk leading to therapeutic failure, which, considering the hazardous nature of most anti-cancers drugs, can have disastrous repercussion for a patient's health. As a result, numerous hospitals have implemented internal regulations to standardise their own procedures and minimise the risk of erroneous treatment of a patient. High performance liquid chromatography (HPLC) remains the gold standard for quantitative analysis of organic compounds as part of daily quality control and is therefore one of most commonly found methods in clinical analytical laboratories attached to preparation facilities.
Mass spectrometry is also a powerful technique for drug screening and analysis, extensively employed in the development of new pharmaceutical compounds or patient monitoring through detection and quantification in body fluids such as serum, urine or saliva [1, 2] . However, it is not currently an option for therapeutic screening applications, due to time constraints of the clinical workflow, requirements for sample preparation, and simply the cost involved. However, some limitations such as high operating costs, relatively low output and the requirement of specialised skills make it less than ideal for routine analysis of chemotherapy preparations [3, 4] . Flowinjection analysis (FIA) spectroscopic based methods are the most commonly implemented, with
Ultraviolet-coupled to Fourier-transform infrared spectrometry (UV/vis-FTIR) probably the most widespread [5, 6] . Recent evolutions have seen the infrared detection replaced by Raman technologies to overcome some of the limitations, but implementation in clinics still requires an aliquot to be taken for injection into the analytical device [7, 8] . Moreover, investigations are ongoing about the possibility to use Raman spectroscopy as a non-invasive tool to overcome some current limitation such as large volume required for FIA, but mostly to avoid any risk in relation to exposure of staff to hazardous solutions [9] .
Vibrational spectroscopic techniques, both infrared (IR) absorption and Raman scattering, deliver specific molecular fingerprinting signatures of samples. They have been extensively studied for biomedical applications [10, 11] can be used and exploited as novel and accurate methods for histopathology [12] , cytology [13] , biopsy characterisation [14] , surgical guidance [15] , treatment monitoring [16] and drug studies [17] . The rapid, cost effective, label free and non-destructive advantages are indeed often pointed out to highlight the benefits of those techniques, but it is the analytical capabilities in terms of both qualitative and quantitative performances are also most relevant for a wide range of clinically oriented applications [18, 19] . IR and Raman spectroscopy are powerful analytical tools widely used for characterisation of organic molecules such as, for example, therapeutic drugs [20] . Although primarily used in industry and research laboratories as screening tools to monitor whether a synthesis process has been successful [21] , coupling the molecular specificity of the spectra collected with optimised quantitative approaches strongly promotes the techniques for therapeutic solution screening in the clinical environment [22] . In previous studies, although encouraging results are documented for monitoring a number of molecules such as ganciclovir [23] or 5FU [24] , directly in the infusion bag, the material used for the packaging, often polystyrene like, also has strong contributions to the spectra that can limit the usable analytical range and lead to difficulties in quantifying and/or identifying the chemotherapeutic drugs accurately [25] . Therefore, such developments remain only at the research level and no translation into the clinic has been achieved as yet, suggesting that the present workflow, entailing analysis of aliquots from the therapeutic solutions is still the most realistic approach.
In prepared from the stock solution using serial dilutions, which were analysed directly with Raman and infrared spectroscopy. The procedure has been repeated 5 times in order to obtain 5 independent sets of spectra. All quoted concentrations refer to the amount of drug present in the solution without taking into account excipients. All samples were prepared freshly on the day of analysis and stored at 4°C in a dark room to avoid photo-damage prior to spectral analysis. ATR-IR spectra have also been recorded for mannitol 10 g.L -1 and 0.15625 g.L -1 which correspond to the concentrations of mannitol found in CERUBIDINE ® 2 g.L -1 and 0.03125 g.L -1 , respectively.
Data collection
The current work flow in place at the UCBO unit (Unité de Biopharmacie Clinique Oncologique, Tours, France) is based on a Multipsec® analyser (MICRODOM, France). The pharmacists receive between 100 and 150 anticancer drug solutions on a daily basis which require analysis and clearance before they are administered to patients. For each individual sample, 1.5 mL is extracted to an aliquot and injected in the analyser with a syringe. The protocols employed in this study for
Raman and Infrared analysis have been derived from the current procedures and designed to improve on the analytical performance.
Raman spectroscopy analysis
Raman spectra were collected using a Labram spectrometer (Horiba Jobin-Yvon, France) equipped with a 690 nm laser source delivering ~10 mW at the sample. 500 µL of the solution were placed in a quartz cuvette and the data was collected by illumining the sample through the wall of the cuvette. In order to ensure maximum reproducibility between measurements, a macro sampling holder, consisting of a cuvette holder attached to the turret of the microscope was employed.
Basically, the laser coming out of the turret is reflected by a 45° mirror and directed through the quartz cuvette. Although the set up requires larger volumes to perform the analysis, the laser is not tightly focused and thus the risk of any photothermal damage is minimised. The spectral range was set between 150-3700 cm -1 , resulting in a spectral resolution of about 2.5 cm -1 , achieved using a 300 lines/mm grating. Two accumulations of 20 seconds were taken for each spectrum. 5 independent sets of dilutions have been prepared for each formulation and analyzed on different days to capture possible instrumental variability in measurements. Additionally, 5 spectra have
been measured for each concentration tested. In total, 200 spectra were recorded over the range of concentrations for each anticancer drug included in this study.
Infrared spectroscopy analysis
Infrared spectra were recorded with a Frontier spectrometer (Perkin Elmer, France) equipped with a multi-reflection (n = 10) Attenuated Total Reflectance (ATR) accessory (Eurolabo, France). The IR spectra collected result from 16 scans performed over the range 600 -4000 cm -1 with a spectral resolution of 4 cm -1 . A background was acquired (64 scans) and ratioed with the sample spectra by the software. 2 μl drops were deposited directly on the diamond crystal and allowed to air dry prior to analysis. 5 independent replicates have been measured for each concentration tested, 5 spectra recorded each time. In total, 200 spectra were recorded over the range of concentrations for each anticancer drug included in this study. The time required to record spectra from one drop is about 5 mins, including drying time and data collection, which is comparable to protocols currently employed at the Hospital of Tours.
Data handling:
The Raman and IR data sets have been pre-processed and analysed using MATLAB (Mathworks, USA). For the purpose of the study, although the preprocessing and data analysis steps have been broken down as individual procedures subsequently applied to data, one should keep in mind that the optimised data processing and analysis protocols are easily incorporated in instrumental software and implemented as automated functions. Once the protocol has been established, total computational time to apply quantitative and discriminative analysis is less than 1 minute a) Discriminative analysis: Raman spectra have been cut in order to focus on the fingerprint region (300-1800 cm -1 ) in which the most relevant spectral features are observed. Pre-processing of Raman spectra included baseline correction, using Lieber or Extended Multiplicative Scattering Correction (EMSC), followed by vector normalisation. While the Lieber algorithm estimates the background by a polynomial function and by an iterative method based on least squares [26] , the EMSC is more advanced approach allowing to correct for additive baseline effects, multiplicative scaling effects, and interference effects [27] . For instance, spectra of deionised water were provided to neutralise its contribution to the Raman spectra collected from the different solutions.
For consistency, infrared spectra have also been reduced to the fingerprint region (600-1800 cm -1 )
prior to being subjected to baseline correction (rubber band) and a vector normalisation. The lower limit of the spectral range for ATR-IR is defined by the crystal material, generating a cut-off of the signal collected. Compared to Raman spectroscopy, ATR-IR therefore has a reduced range in the finger print region, which is inherent to the technique. Once pre-processing was completed, both Raman and IR spectra were analysed by PCA [28] and PCA-FDA (PCA-FactorialDiscrimination-Analysis) [29] . Although PCA is a well-established method for rapid evaluation of the data, highlighting the spectral variability present in data sets, more advanced approaches such as PCA-FDA are required to deliver information about the discriminative performance of the techniques. PCA-FDA includes a 100 fold cross validation through a leave K-out cross validation routine. This approach ensures no replicate of a given sample can be found in both the calibration and validation sets and avoids over optimistic outcome of the quantitative analysis [30] . 1/3 of the data is selected as a test set, while the 2/3 of the remaining samples were used as calibration and validation sets. The test set is kept constant and at each iteration, different combinations of randomly selected calibration/validations sets are tested. Ultimately, the results are presented in the form of confusion matrices, allowing calculation of the specificity and sensitivity of the discrimination analysis performed.
b) Quantitative analysis: Normalisation procedures should be avoided to preserve the intensity to concentration relationship in the data. Therefore, only an offset correction has been applied for the spectra pre-processing. PLSR remains the most relevant analysis to evaluate the possibility of performing quantitative analysis of systematically varying vibrational spectra [31, 32] . It is a supervised multivariate technique that is highly specific for quantitative methods, and is usually performed via two steps: calibration and validation. Therefore, similarly to the PCA-FDA a 100 fold leave K-out cross validation was implemented. The output of PLSR provides performance criteria defined under the linearity (R 2 ) and precision, also called Root Mean Square
Error for Cross Validation (RMSECV). Additionally, the lower Limit Of Detection -lower LOD)
has been estimated based on the work published by Allegrini and al
Results and Discussion

UV characterisation of anthracycline formulation
Anthracyclines are a group of cytotoxic compounds used as treatment of a wide variety of cancers, from leukemia, thyroid, lung and other neoplasia, ovarian, breast, lung and gastric cancer [33] leading to a large number of solutions being prepared on a daily basis for patients under chemotherapeutic treatment. Doxorubicin, epirubicin and daunorubicn are composed of tetracycline aromatic moiety attached to a sugar moiety of daunsamine via a glyosidic bond. As displayed in Figure 1 , these 3 anthracyclines have the same aromatic chromophore and the difference between them concerns the side chains. Notably, epirubicin is a stereoisomer of doxorubicin, and differs from it only in the orientation of the hydroxyl group of the hexapyranosyl sugar [33] . Daunorubicin differs from doxorubicin only in the shorter side chain terminated with a methyl group instead of a primary alcohol group. As a direct consequence, those molecules cannot be discriminated using UV spectrophotometry. The absorbance spectra were collected for the 3 molecules in their commercial forms (doxorubicin from TEVA®, epirubicin from MYLAN® and daunorubicin from CERUBIDINE®. These spectra have the same profile, with the two main maxima located at ca. 480 and 500 nm. NaOH, HCl and mannitol (a sugar) present in the commercial forms do not have direct contribution to the UV/Vis spectra in this range, and thus the absorbance is solely derived from the drugs. While quantitative analysis is expected to be achievable with UV absorbance spectroscopy, difficulties to perform specific identification of the chemotherapeutic drugs are understandable. As they contain information of all the moieties of the molecule, rather than just the chromophoric π-conjugated structures, vibrational spectra are richer in specific molecular structural information than UV-vis absorption spectra. This study aims to demonstrate this and optimise protocols to implement the analysis in a clinical workflow. around 450 cm -1 and 1300 cm -1 in the water spectrum are respectively assigned to the quartz cuvette and the glass of the focusing lens of the macro adapter used. In comparison to the short side chains, the intensity of the peaks associated to the conjugated chromophores is dominant, due to their high Raman activity. Consequently, no major spectral differences can be observed between the 3
formulations. Moreover, in contrast, molecules such as NaOH and HCl do not have any significant contribution to the spectra. In the solution of 2 g.L -1 CERUBIDINE®, mannitol is found at 10 g.L -1 . Despite the relatively high concentration, the Raman spectrum collected from the mannitol aqueous solution does not exhibit strong features, and the only difference with the water spectrum is at 886 cm -1 , where a weak peak arises from the broad background (spectrum 2e). it comes to discriminating data sets based on the molecular information of the spectra, the overall intensity should be disregarded in favour of band positions, number and intensity ratios.
Consequently, in the present study, it has been considered more relevant to subject the spectra to both baseline correction and vector normalisation prior to PCA-FDA. Thus, the concentration parameter has been removed from the analysis, focusing solely on the variations described above.
Moreover, two methods for baseline correction have been evaluated, the Lieber correction [38] and EMSC [39] .
PCA is a well-established unsupervised approach for rapid evaluation of spectral variability in complex data sets. Intensively used for analysis of IR and Raman spectra collected from biological samples, it readily allows visualisation of possible discrimination of samples using scatter plots [40, 41] . Figure 3A The loadings corresponding to each PC are displayed in Figure 3B , highlighting the spectral features leading to the distribution of the data points in the scatter plot. The features of the loading of PC2 are common to the Raman spectra of both compounds, as shown in Figure 2 , but the differentiating features suggest that small shifts can result from the different stereo-chemistry of the molecules.
Although PCA performed using a single concentration (i.e. 2 g.L -1 ) exhibits clear separation of the three clusters and thus possible identification of the different chemotherapeutic forms, it is also important to address the need to perform discriminant analysis as an overall classifier, including all concentrations. The spectra in Figure 2 illustrate how similar the Raman spectra of the three formulations are, and the PCA in Figure 3 indicates that any variations between them are minor differences in peaks positions and intensities. Applying PCA to the range of possible combinations of concentrations would require considerable effort, and thus other multivariate approaches such as PCA-FDA need to be implemented. All the different concentrations and drug types have been considered as distinct groups to classify (n = 24). The approach is supervised and implementation of a cross validation procedure is necessary to ensure the robustness of discrimination observed.
Specifically, 1/3 of the data was used as a validation set and for each iteration of the 100-fold leave K-out cross validation, calibration and validation sets were constituted from the 2/3 of the remaining spectra. To better appreciate the specificity and sensitivity of the discrimination, at each iteration of the cross validation, results obtained with a model based on 4 principal components are reported in a confusion matrix (Table 3 ). This step of the analysis aims purely to discriminate the different anti-cancer drugs without any significance given to their concentrations. Therefore, successful classification was judged solely on the ability to identify the correct drug corresponding to the test spectra, irrespective of the concentration assignment. Although the overall specificity and sensitivity obtained are above 90%, the results are concentration and molecule dependent, and in some cases exhibit rather low values, as for example the TEVA® S7 (specificity = 85%), MYLAN® S1 (specificity = 75%) or CERUBIDINE® S1 (sensitivity 50%) ( Table 3) .
Although the results are encouraging, observation made in Figure 2 of minimal spectral differences between TEVA® and MYLAN® formulations, the specificity of the classification achieved is somehow surprising. Raman spectroscopy is a technique particularly sensitive to changes of the light scattering when performing analysis on liquid samples. While the dynamic range of concentrations tested could lead to inconsistencies in the measurements, solutions of commercial formulations also contain excipients which possibly contribute to the spectra collected, not necessarily in terms of spectral features considering the concentrations, but rather affecting the baseline (or background) through scattering [42] . For this reason, more advanced baseline correction, taking into account the water spectrum has been performed by means of EMSC coupled to vector normalisation prior to PCA ( Figure 3C and D) . While the scatter plot from the PCA still displays clear separation between data groups according to formulation (Figure 3C) Consequently, when performing the PCA-FDA, the outcome is also affected and the overall specificity and sensitivity are now found to respectively be between 64.4% -72.5% and 53.3% -59.2% with the classification model constructed using 3 principal components (Table 4) . A number of concentrations exhibit values below 50%, which indicates that a non-negligible number of misclassifications have occurred, thus raising some serious concerns about the choice of data preprocessing having high impact on the analysis outcome and consequently the robustness of Raman spectroscopy measurements for drug identification can be questioned. In some cases, such as TEVA® S3 and CERUBIDINE® S4, there is obviously a reduced reliability in the drug identification, which for high concentrations can generate higher risks of dose intoxication of patients. Moreover, at lower concentrations, the accuracy is also not suitable for accurate classification, suggesting the specificity of Raman is not sufficient. EMSC is an advanced correction method able to remove instrumental and/or experimental interferences. However, despite applying such correction, the outcome of the PCA-FDA remains quite disappointing, suggesting that the sensitivity and specificity observed are directly linked to the ability of the technique to discriminate the 3 therapeutic solutions rather than the underlying source of variability. 
(grey), water (violet). Spectra are offset for clarity.
While examination of spectra allows identification of the anti-cancer drug with a reasonably high degree of accuracy, the linear relationship existing between the intensity of the peaks and the concentrations prepared can be examined and used as a quantitative prediction model using PLSR.
Due to the experimental macro set up used in this study, the reproducibility achieved during the measurements enables unambiguous monitoring of the decrease of the peak intensities according to the dilutions performed, as illustrated for the example of TEVA® in Figure 4 . PLSR is a reliable method to evaluate the quantitative information contained in the data sets collected. However, in order to ensure maximum statistical relevancy, cross validation procedures are generally implemented [30] , in order to demonstrate that the analysis is not biased, but also to test the robustness of the predictive model used. Considering the size of the number of spectra available for each concentration, a 100-fold leave K out cross validation with 2/3 of spectra used as calibration and the remaining 1/3 as validation has been preferred for this study. The calibration and validation are therefore completely independent and selected randomly at each iteration of the cross validation, enabling testing of numerous data combinations. The first graph generated during the analysis represents the Root Mean Square Error of Calibration (RMSEC) according to the number of dimensions used to regress the data ( Figure 5A ). As a supervised method, and aiming to deliver the lowest RMSEC and thus the best precision, a gradual decrease towards 0 is expected as the number of dimensions employed in the model increases. Once the model has been established using the calibration set, it is then evaluated with the validation spectra. The Figure 5B exhibits first a steep decrease in the RMSECV (validation) before slightly increasing a stabilizing around 0.015 g.L -1 . All dimensions calculated from the calibration set are not relevant to the quantification, and according to Figure 5B , above 3 dimensions over fitting of the data could actually affect the precision of the predictive model. Consequently, the regression plot has been implemented using three dimensions, and is presented in Figure 5C . The correlation between observed concentration (true concentrations) and predicted concentrations (experimental concentrations) delivers a linear trend characterised by R 2 value of 0.9997 (Table 5 ). The error bars illustrate the standard deviation calculated from the 100 fold cross validation and further support the high reproducibility of the measurements. The overall RMSECV reached was found to be 0.0127 g.L -1 for TEVA® ( Table 5 ). The numbers of dimensions used to construct the PLSR predictive models, respectively 3, 5 and 5 for TEVA®, MYLAN® and DNR, are also indicated in Table 5 . Figure 5D shows the weighting vector corresponding to the PLSR analysis performed on TEVA® solutions. It represents the wavenumbers used to construct the predictive models, confirming the molecular specificity of the analysis has been preserved. 
Figure 6: Mean ATR-IR spectra recorded from TEVA® (A), MYLAN® (B), CERUBIDINE® (C) formulations and Mannitol (D). All spectra were recorded from solutions with final concentration of anticancer drugs at 2g.L -1 . Spectra are offset for clarity.
Although recent work has supported the feasibility to perform IR quantitative analysis with ATR-IR from liquid samples [32, 43] , in the present study the anti-cancer drug concentrations involved are not sufficient to overcome the strong contribution of the water bands, which completely swamp the features of interest (data not shown). Consequently, air drying of samples following deposition onto the ATR crystal is required to collect exploitable data. Figure 6 displays the fingerprint region of mean spectra collected from the 3 different formulations. TEVA® and MYLAN® ( Figure 6 A and B) deliver spectral signatures with high degree of similarity, but comparison of the peaks positions would suggest some variations in the range 700-1200 cm -1 can be observed (Table 6 ).
Interestingly, the major difference compared to Raman spectroscopy is the weaker contribution of conjugated chromophores in the signatures collected. Consequently, other contributions from side chains and excipients can be somehow enhanced and more easily detected. For instance, the CERUBIDINE® mean spectrum differs from the other two without any possible ambiguity. This can be explained by the presence of a high amount of mannitol in the formulation, obviously delivering strong features in the IR signature (Figure 6d) . Summarised in transmission can lead to Mie or resonant Mie scattering effects [44] , direct deposition of the solution on the ATR crystal minimises such phenomena. Consequently, only some offset in the data collected is observed according to the concentrations analysed, but such effects are easily compensated by implementation of a simple straight baseline subtraction such as the rubber band employed here. A rubber band correction with only 2 nodes at 1800 cm -1 and 600 cm -1 has the effect of bringing the spectral baseline down to 0 across the spectral range. Prior to performing the discriminant analysis, the concentration parameters have been removed using a vector normalisation to rescale all spectra.
The PCA scatter plot displays strong separation of the three formulations according to PC1 and PC2, accounting respectively for 98.7% and 0.82% of the explained variance ( Figure 7A ).
Similarly to Raman spectra, PC1 unambiguously differentiates TEVA® ( Figure 7A This observation supports the presence of small variations in bands positions as previously witnessed and reported in Table 6 . The features of loading 2 confirm that the discrimination is based on the differing spectroscopic profiles of the compounds but due to the scattering of CERUBIDINE® data points over the 2 other clusters in that dimension, it is unclear the discrimnation is genuine and peaks observed specific. Pairwise PCA is the most direct and unambiguous analysis to highlight the presence of discriminative wavenumbers between 2 datasets [28] . Figure 7C and 7D displays respectively the scatter plot and loading 1 for the PCA applied to TEVA® and MYLAN®. In absence of the CERUBIDINE® and associated strong mannitol bands the scatter plot naturally reorient itself to display a clear separation of TEVA® and MYLAN® along PC1 with an explained variance of 91.8%. The loading 1 corresponding to PC1 exhibits a quite large number of features but interestingly some of most intense located at 767 cm -1 , 1014 Table 6 . Despite, pairwise PCA is a relevant approach to investigate inter and intra data sets variability, it becomes relatively difficult to evaluate all combinations of data and estimate the discrimination rate when the number of samples is increasing. Therefore, more advanced methods such as PCA-FDA can be used.
The outcome of the PCA-FDA obtained using 3 principal components is presented in Table 7, whereby, once again, the specificity and sensitivity has been calculated for each concentration analysed and for each drug. Using the ATR-IR spectra for discriminative analysis leads to high rates of correct classification with overall values equal or above 99.4%. A more detailed breakdown of the results shows that only the lowest concentrations tested, corresponding to 0.03125 g.L -1 , do not deliver 100% specificity and sensitivity for all 3 formulations. However, with 90% as the lowest outcome, the results remain quite satisfactory for accurate and reliable identification of formulations tested in respective formulations. Considering the strong sugar features in the IR spectra collected from CERUBIDINE® it is obvious mannitol plays a major role in the discrimination. Despite, the main concern of the study is to investigate discrimination of solutions rather than solely the anticancer drugs, one could ask about the specificity of the analysis to actually differentiate the therapeutic solution containing Therefore, the discrimination of CERUBIDINE® observed in the PCA-FDA is a combined contribution of both mannitol and other ingredients including the anticancer drug. Similar observation are made with all concentrations included in this study (data not shown) which is perfectly understandable as the mannitol/daunorubicin ratio remains identical for all samples due to the same dilution factor applied during the preparation. 
(grey). Spectra are offset for clarity
Observation of the ATR-IR spectra collected from a set of TEVA® solutions highlights that the intensity of the absorbance tends to decrease according to concentration (Figure 9 ). It has been demonstrated that, while ATR-IR measurements can be used for quantitative analysis, the approach has a limited range of concentrations over which the Beer-Lambert law can be directly applied, whereby high concentration samples lead to a plateau effect with a loss of the linear relationship [43] . As the concentration increases, the thickness of the deposited residue film increases, to the extent that is comparable to the spatial extent of the evanescent field of the ATR.
This can be accounted for by additional dilution of the higher concentrations. However, in the present study, it appears the dynamic range of concentrations is within the range of linearity of absorbance response. Similar to the case for Raman, the ATR-IR spectra have been subjected to PLSR analysis in order to evaluate how well correlated the spectral variations are with the concentration of the anticancer formulations. Figure 10 presents the different steps performed on the TEVA® form, as described previously in section 3.2.3. As observed with the Raman, the weighting vector extracted from the PLSR analysis is almost an identical copy of the mean spectra presented in Figure 10D , once more illustrating the molecular specificity of the analysis performed.
However, the behaviour of the RMSECV according the number of dimensions included in the analysis strongly differs compared to the Raman analysis. It tends to gradually decrease, with no clearly defined optimal number of dimensions which would ensure no overfitting of the model.
Examination of the latent variables suggests that only the first 3 exhibit strong relevant features, while subsequent ones become increasingly dominated by noise and random bands. Therefore, considering the limited number of data in this investigation, it was deemed preferable to limit the number of dimensions to 3, in order not to deliver over optimistic results for the ATR-IR analysis.
Ultimately, the outcome of the PLSR analysis delivers RMSECV higher than those observed with However, although a multi-reflection crystal has been used, compared to the macro set up for the Raman experiments, the repeatability in the IR analysis remains lower, leading to loss of precision.
In order to avoid over fitting of the results, the number of dimensions has been limited to 3 for the of the sample thickness, but also the risk of heterogeneous distribution and therefore sampling in multicomponent samples [45] . In recent years, concerns over the so-called "coffee ring effect" have been raised, in relation to ATR FTIR analysis of dried droplets. The effect refers to the tendency of molecular species to accumulate at the edge of the drop during the dry process [43] [44] . Depending on the sample concentration, the coffee ring effect can also lead to complete loss of the signal simply because the sample accumulates outside the area of measurement of the ATR crystal [41] . Different types of crystals are commercially available, defined by the material of the crystal (for example diamond or germanium) but also the number of internal reflections.
Importantly, the size of the crystal is also different and while a single reflection accessory delivers no signal from chemotherapeutic solutions analysed, due to this coffee ring effect (data not shown), the multi-reflection diamond crystal used in the present study offers a wider area for collection thus enabling the 2µL to be completely deposited within the recording area. However, although the multi-reflection accessory partially solves the limitation due to coffee ring effect, the heterogeneity of the samples after drying remains quite high, possibly also related to the precision of manual deposition of small volumes. 
Overall discussion
Direct comparison between infrared and Raman spectroscopy has been conducted for the for more reliable identification of the stock solution used to prepare the diluted solution. In the present study, TEVA®, MYLAN® and CERUBIDINE® are the one and only brand used for respectively doxorubicin, epirubicin and daunorubicin. Thus the spectral bands identified and used for discrimination will be reproducible and consistent over time. At present, quality control laboratories in hospitals typically employ flow injection analysis which is able to deliver accurate quantification for the majority of the 100+ solutions tested daily. The technique lacks the required specificity, however, when challenged with the discrimination of isomers such as TEVA®, MYLAN® and CERUBIDINE®, which display similar absorbance in the visible range, which can result in significant delays in administration of the solutions on a daily basis. As an augmentation to the current workflow, ATR-IR provides a potential solution for the rapid differentiation of the solutions. Performing the ATR analysis requires small volumes (few µL) compared to other current systems with injection of aliquots of at least 1.5 mL necessary. Considering the whole process of data analysis can be automated and completed in less than 1 minute, the overall time to get the result does not exceed 5 mins, which is comparable to systems already in use. Ultimately, ATR-IR spectroscopy is a cost effective technique with compact bench top apparatus that does not represent a huge capital investment and are increasingly user friendly, such that the data preprocessing and analysis routines can be easily incorporated into the instrument software and implemented in an automated protocol.
Conclusion
Both To summarise, ATR-IR spectrophotometry remains a cost effective, rapid and user friendly method which with optimization of methods would lead to fast implantation in the hospital routine.
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